Glenpharma AB
Glenpharma AB is a small privately owned research spin-off from Pfizer-Pharmacia, formed in Sweden in 2002 to exploit novel technology patented by its founders.
We offer patented synergistic combinations of biopolymers for
a) accelerated repair of acute tendon /ligament injuries in human applications ( such as sprained ligaments / tendons in shoulder, elbow, knee, ankle, etc , in both sports injury scenarios and in the elderly ) , or in veterinary indications (e.g. high performance horses) . The product accelerates healing at least 3 times faster than the normal healing process.
b) for prevention of unwanted adhesions between tissues after major thoracic, abdominal , fertility or orthopedic surgery. In studies on prevention of difficult adhesions after cardiac surgery, for example, adhesion scores were < 10% of those in control groups.
c) for effective control of acute pain in advanced joint disease (osteo-arthritis (OA) . Clinical documentation in advanced OA indicates that onset of pain relief is much faster and of longer duration than current standards for viscosupplementation.
Each of the above biopolymer "viscous fluid implants" are also ideal drug delivery media for treatment of ancillary complications.
All component biopolymers are well documented APIs, i.e. without the toxicty and other regulatory issues generally associated with "New Chemical Entities". Glenpharma´s current patent protection covers most major international markets including USA, Europe and P R China.
Glenpharma is primarily seeking Chinese partners for out-licensing within the fields of orthopedics or major surgery.. If neccessary , we can offer contract-manufacturing options in Europe if not available in China.
Senior Scientist Peter Buckley
CEOGlycoSeLect Ltd
Our company develops and manufactures technology and applications for glycoprotein separation and analysis. We are focussed on the biopharmaceutical industry. We also have customers in medical diagnostic and cosmetic companies.
Our facility is based on the campus of Dublin City University in Ireland.
We have developed an extensive network of contacts not only customers but also opinion leaders in glybiology.
Robert Dunne
CEOHebeCell Corporation
Dr. John Lu is the President and CEO of HebeCell. Before establishing HebeCell, John was the Senior Director of Research at Advanced Cell Technology/Ocata Therapeutics, which in 2016 was acquired by Astellas, the second-largest pharmaceutical company in Japan. John is an expert in stem cell biology and regenerative medicine with 20 years of experience in the field.
Dr. Allen Feng is the Chief Scientific Officer of the HebeCell Corp. Prior to establishing HebeCell, he was the Director of Cell Biology of Semma Therapeutics, which was acquired by Vertex Pharmaceuticals in 2019. Prior to Semma, Allen worked as R&D Head of Stem Cell Bioprocessing Group at EMD Millipore, and also served as Director and Senior Scientist at Advanced Cell Technology /Ocata Therapeutics.
John Lu
President and CEOHEC Pharm
HEC Pharm focuses on the development and commercialization of pharmaceuticals for the therapeutics of anti-infectious diseases, metabolism disorders and oncology. We are hunting for the opportunities of co-development and in-license of the candidates with the potential therapeutics in previous fields.
Lisha Chen
Senior Business Development ManagerHelsinn Pharmaceuticals China
Enrico Magnani
General ManagerImmunoBiochem
Anton Neschadim
DirectorIncuron, Inc.
Key advantages of curaxins based on current preclinical and early clinical data include:
- novel mechanism of action that would bring the additional treatment option for advanced and relapsed tumors, as well as potential to overcome resistance to previous treatments;
- favorable pharmacology and manageable safety profiles;
- low potential for serious drug-drug interactions providing opportunities for combinatorial therapeutic regimens;
- broad activity in different tumor types that may open wider market opportunities;
- focused phase 2 clinical study program can establish faster clinical proof of concept and build toward accelerated regulatory approval.
Incuron owns a worldwide patent portfolio, including the composition of matter and therapeutic uses of the compounds.
Kristina Zakurdaeva
CEOInorbit Therapeutics ab
InorbitTX is a virtual drug discovery and development company focussed on the treatment of fatty liver diseases NAFLD / NASH. Its lead project, the FXR agonist IOT022 is currently in late pre-clinical testing. IOT022 differentiates very well from competitor compounds, as it mitigates the risk for pruritus and for drug induced liver injury, seen with competitors. It gives IOT022 an excellent best-in-class opportunity. We look for funding to complete for IND and for Phase I. We also look for partnering for the Chinese / Asian market.